Cargando…

Patterns of mortality after prolonged follow-up of a randomised controlled trial using granulocyte colony-stimulating factor to maintain chemotherapy dose intensity in non-Hodgkin's lymphoma

The effect of utilising granulocyte colony-stimulating factor (G-CSF) to maintain chemotherapy dose intensity in non-Hodgkin's lymphoma (NHL) on long-term mortality patterns has not been formally evaluated. We analysed prolonged follow-up data from the first randomised controlled trial investig...

Descripción completa

Detalles Bibliográficos
Autores principales:	Clamp, A R, Ryder, W D J, Bhattacharya, S, Pettengell, R, Radford, J A
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2008
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2480980/ https://www.ncbi.nlm.nih.gov/pubmed/18594529 http://dx.doi.org/10.1038/sj.bjc.6604468

Ejemplares similares

Recombinant human granulocyte colony-stimulating factor (filgrastim) following high-dose chemotherapy and peripheral blood progenitor cell rescue in high-grade non-Hodgkin's lymphoma: clinical benefits at no extra cost.
por: Lee, S. M., et al.
Publicado: (1998)

Incidence of neutropenia, chemotherapy delivery, and use of colony-stimulating factor in patients with non-Hodgkin lymphoma of different age groups
por: Pettengell, Ruth, et al.
Publicado: (2011)

Pulmonary toxicity after granulocyte colony-stimulating factor-combined chemotherapy for non-Hodgkin's lymphoma.
por: Yokose, N., et al.
Publicado: (1998)

Serious pulmonary complications in patients receiving recombinant granulocyte colony-stimulating factor during BACOP chemotherapy for aggressive non-Hodgkin's lymphoma.
por: Lei, K. I., et al.
Publicado: (1994)

Hodgkin lymphoma treatment with ABVD in the US and the EU: neutropenia occurrence and impaired chemotherapy delivery
por: Schwenkglenks, Matthias, et al.
Publicado: (2010)

Male fertility after VAPEC-B chemotherapy for Hodgkin's disease and non-Hodgkin's lymphoma.
por: Radford, J. A., et al.
Publicado: (1994)

High-dose intensity cyclophosphamide, epidoxorubicin, vincristine and prednisone by shortened intervals and granulocyte colony-stimulating factor in non-Hodgkin's lymphoma: a phase II study.
por: Pronzato, P., et al.
Publicado: (1998)

Risk factors for neutropenic fever in non- Hodgkin’s lymphoma patients with primary granulocyte colony-stimulating factor prophylaxis
por: Kim, Yu Ri, et al.
Publicado: (2021)

Association of reduced relative dose intensity and survival in lymphoma patients receiving CHOP-21 chemotherapy
por: Pettengell, R., et al.
Publicado: (2008)

Effects of the in vivo Administration of Recombinant Human Granulocyte Colony‐stimulating Factor Following Cytotoxic Chemotherapy on Granulocytic Precursors in Patients with Malignant Lymphoma
por: Ema, Hideo, et al.
Publicado: (1989)

Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF) Induced Severe Atypical Rash in a Patient of Non-Hodgkin's Lymphoma
por: Singh, Gautam Kumar, et al.
Publicado: (2022)

Economic costs of chemotherapy-induced febrile neutropenia among patients with non-Hodgkin’s lymphoma in European and Australian clinical practice
por: Weycker, Derek, et al.
Publicado: (2012)

Increased mobilization and yield of stem cells using plerixafor in combination with granulocyte-colony stimulating factor for the treatment of non-Hodgkin’s lymphoma and multiple myeloma
por: Pelus, Louis M, et al.
Publicado: (2011)

Development of Site-Specific PEGylated Granulocyte Colony Stimulating Factor With Prolonged Biological Activity
por: Kumari, Monika, et al.
Publicado: (2020)

Granulocyte colony-stimulating factor (filgrastim) in chemotherapy-induced febrile neutropenia
por: Advani, S. H., et al.
Publicado: (2010)

Use of granulocyte colony-stimulating factor in patients with chemotherapy-induced neutropaenia
por: Shokane, Lucky L., et al.
Publicado: (2023)

Granulocyte-macrophage colony-stimulating factor (GM-CSF) allows acceleration and dose intensity increase of CEF chemotherapy: a randomised study in patients with advanced breast cancer.
por: Ardizzoni, A., et al.
Publicado: (1994)

Routine Primary Prophylaxis for Febrile Neutropenia with Biosimilar Granulocyte Colony-Stimulating Factor (Nivestim) or Pegfilgrastim Is Cost Effective in Non-Hodgkin Lymphoma Patients undergoing Curative-Intent R-CHOP Chemotherapy
por: Wang, Xiao Jun, et al.
Publicado: (2016)

Comparison of the effects of pegylated granulocyte-colony stimulating factor and granulocyte-colony stimulating factor on cytopenia induced by dose-dense chemotherapy in breast cancer patients
por: Ashrafi, Farzaneh, et al.
Publicado: (2018)

Effect of granulocyte colony-stimulating factor on toxicities after CAR T cell therapy for lymphoma and myeloma
por: Miller, Kevin Charles, et al.
Publicado: (2022)

In vitro Colony Forming Cells and Colony Stimulating Factor in Chronic Granulocytic Leukaemia
por: Goldman, J. M., et al.
Publicado: (1974)

Maintaining Efficacy But Decreasing Toxicity in the Treatment of Hodgkin Lymphoma
por: Ansell, Stephen M.
Publicado: (2017)

Treatment outcomes and relative dose intensity of chemotherapy in patients with advanced Hodgkin lymphoma
por: Rožman, Samo, et al.
Publicado: (2022)

Lymphoma survivors’ experience of participation in a home-based intervention post-chemotherapy
por: Hathiramani, Suchita, et al.
Publicado: (2019)

Long-term follow-up of patients treated with radiotherapy alone for early-stage histologically aggressive non-Hodgkin's lymphoma
por: Spicer, J, et al.
Publicado: (2004)

Evaluation of neuropathy during intensive vincristine chemotherapy for non-Hodgkin's lymphoma and Acute Lymphoblastic Leukemia
por: Dorchin, M, et al.
Publicado: (2013)

Identification of granulocytic myeloid-derived suppressor cells (G-MDSCs) in the peripheral blood of Hodgkin and non-Hodgkin lymphoma patients
por: Marini, Olivia, et al.
Publicado: (2016)

Subcutaneous Administration of Recombinant Human Granulocyte Colony‐stimulating Factor (KRN8601) in Intensive Chemotherapy for Patients with Advanced Lung Cancer
por: Eguchi, Kenji, et al.
Publicado: (1990)

Granulocyte colony-stimulating factor and leukemogenesis.
por: de Figueiredo, Lorena Lobo, et al.
Publicado: (2004)

CODE chemotherapy with and without granulocyte colony-stimulating factor in small-cell lung cancer.
por: Fukuoka, M., et al.
Publicado: (1997)

Patterns of granulocyte colony–stimulating factor prophylaxis in patients with cancer receiving myelosuppressive chemotherapy
por: Gawade, Prasad L., et al.
Publicado: (2020)

Effect of granulocyte colony-stimulating factor (G-CSF) on chemotherapy-induced oral mucositis
por: Katano, Mitsuo, et al.
Publicado: (1995)

Relaxation versus exercise for improved quality of life in lymphoma survivors—a randomised controlled trial
por: Hathiramani, Suchita, et al.
Publicado: (2020)

Phase I/II study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancer.
por: Bronchud, M. H., et al.
Publicado: (1987)

Sarcoid Reactions after Chemotherapy for Hodgkin’s Lymphoma
por: Wirk, Baldeep
Publicado: (2010)

Reduced-Intensity Chemotherapy in Patients With Advanced-Stage Hodgkin Lymphoma: Updated Results of the Open-Label, International, Randomised Phase 3 HD15 Trial by the German Hodgkin Study Group
por: Engert, Andreas, et al.
Publicado: (2017)

Prophylaxis of chemotherapy-induced febrile neutropenia with granulocyte colony-stimulating factors: where are we now?
por: Aapro, Matti, et al.
Publicado: (2010)

Granulocyte Colony-Stimulating Factor Restored Impaired Spermatogenesis and Fertility in an AML-Chemotherapy Mice Model
por: Michailov, Yulia, et al.
Publicado: (2021)

Serum Granulocyte Colony-Stimulating Factor and Alzheimer's Disease
por: Barber, Robert C., et al.
Publicado: (2012)

Granulocyte Colony-Stimulating Factor in Amniotic Fluid
por: Raynor, B. Denise, et al.
Publicado: (1995)

Cannot write session to /tmp/vufind_sessions/sess_j80f37bk1d3jj8p9dkd5irnh0u